Synonyms: BGB-116673 | BGB116673 | compound 14 [WO2021219070A1]
Compound class:
Synthetic organic
Comment: The chemical structure for catadegbrutinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as a Bruton tyrosine kinase (BTK) degrader with antineoplastic potential. A structure match in PubChem aligns catadegbrutinib with the company research code BGB-116673/BGB116673, and with a structure claimed in Beigene's patent WO2021219070A1 [1]. BGB116673 is a conjugate of a BTK inhibitor with an E3 ligase ligand. As a PROTAC class degrader the resulting molecule functions to recruit targeted proteins to E3 ubiquitin ligase for proteasomal degradation of wild type and mutated forms of the BTK protein.
|
|
Bioactivity Comments |
WO2021219070A1 provides a DC50 of 0.72 nM for degradation of BTK by compound 14 (which is structurally identical to catadegbrutinib), with very low cytotoxicity in HEK cell culture [1]. |